Posts

Showing posts with the label Anticoagulation

Left Atrial Appendage Ostial Stenosis in a Patient with Atrial Flutter and Asymmetric Septal Hypertrophy-Juniper Publishers

Image
JUNIPER PUBLISHERS - OPEN ACCESS JOURNAL OF CARDIOLOGY & CARDIOVASCULAR THERAPY   Abstract Isolated left atrial appendage ostial stenosis has been previously described. The clinical implications of this anomaly are uncertain. The relative stasis behind ostial stenosis may result in systemic embolization, particularly stroke. We report the case of a 55 years old woman who has left atrial appendage ostial stenosis. She was admitted for radiofrequency catheter ablation of atrial flutter. We present this case to discuss whether life-long anticoagulation would be necessary for stroke prevention after successful radiofrequency catheter ablation Keywords: Left atrial appendage ostial stenosis; Transesophageal echocardiogram; Anticoagulation; Stroke prevention Abbreviations: AFL: Atrial Flutter; AF: Atrial Fibrillation; LVOT: Left Ventricular Outflow Tract; RFCA: Radiofrequency Catheter Ablation; TEE: Transesophageal Echocardiogram; LAA: Left Atrial Appendage ...

A Study of 1,236 Patients Supporting the Use of Unfractionated Heparin With or Without Glycoprotein IIb/IIIa Inhibitors over Bivalirudin in Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Changing Trend-Juniper Publishers

Image
JUNIPER PUBLISHERS-OPEN ACCESS JOURNAL OF CARDIOLOGY & CARDIOVASCULAR THERAPY Background The use of antithrombotic therapy such as heparin and bivalirudin are standard of practice in managing ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with a Class I recommendation. Recently the American College of Cardiology published in JACC: Cardiovascular Interventions a study analyzing the trends in anticoagulant use among 513,775 PCIs for STEMI from July 2009 through December 2014 utilizing information available from the National Cardiovascular Data Registry CathPCI Registry. In this study, bivalirudin was associated with a reduction in adverse bleeding events attributed to an increased use of glycoprotein IIb/IIIa inhibitors (GPI) alongside UFH. Objective: To report the efficacy and safety outcomes of UFH with routine use of GPI in primary PCI for STEMI in a high-risk population. Methods: Single center, re...